Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 6Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

enzalutamide 9Abiraterone Acetate 5rucaparib 2Prednisone 2Docetaxel 2pembrolizumab 1fluzoparib 1apatinib 1abiraterone 1Blood Specimen Collection 1Biopsy 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration Resistant Prostate Cancer × fluzoparib × Clear all
NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡